Armstrong Says FDA "Assured" OTC Access Of Reformulated Primatene Mist
This article was originally published in The Tan Sheet
Executive Summary
Armstrong Pharmaceuticals says FDA "assured" the firm that it can sell a proposed reformulated epinephrine inhaler OTC, if approved, despite opponents who say asthma relief is an inappropriate self-medication indication
You may also be interested in...
FDA Expectation For Replacement OTC Inhaler Remains Unfulfilled
The only inhalers to treat asthma available after Dec. 31 will be prescription products.
Asthma Treatment OTC Switches Would Face Tough Barriers
Prescription asthma drugs on the brink of patent expiry could breathe new life into Rx-to-OTC switches, but not without fierce opposition from some health care providers.
FDA Final Rule For OTC Inhaler Labeling Requires Death Warning
FDA disagrees with industry comments regarding the health risks of using OTC asthma inhalers, rejecting suggested language for the final monograph covering asthma and bronchodilator drugs.